Effects & safety · The human layer
PT-141 effects: the measured benefits, the reported downsides, and who has reason for caution.
A plain-English account of what the bremelanotide trials measured, what people report, and the cited safety cautions — kept in separate, clearly ruled lines.
The short version
PT-141 effects fall into three honest groups. First, the benefits the trials measured: in women with low desire that caused distress, bremelanotide produced a small but real improvement in desire and a small reduction in distress [3]. Second, the side effects: nausea was common — about 40% of women over a year of use — along with flushing and headache [4]. Third, the cautions: the label warns about a short-lived rise in blood pressure, so it is not for people with uncontrolled high blood pressure or heart disease [7].
One thing to keep straight: the measured benefits come from controlled trials in premenopausal women. Anything else you read — about men, or about "performance" — is not an approved finding [7]. Below, the cited evidence is kept clearly separate from what people report online.
PT-141 benefits — what the studies measured
The benefit that earned approval is specific and quantified. Across the two Phase 3 RECONNECT trials in 1,267 premenopausal women with HSDD, bremelanotide improved the FSFI-desire score by an integrated +0.35 and reduced desire-related distress (FSDS-DAO item 13) by an integrated −0.33, both with P<.001 against placebo over 24 weeks [3]. A 52-week open-label extension found those gains were sustained over a year of as-needed use [4].
The mechanism behind the benefit was imaged directly. In a 2022 fMRI study of 31 women, MC4R activation increased reported sexual desire for up to 24 hours and changed brain processing of erotic stimuli, with enhanced amygdala–insula connectivity [5]. A 2026 systematic review and meta-analysis pooled the trial data and reported that bremelanotide improved total FSFI plus the desire and arousal subscales [13]. These are cited measurements, not promises.
PT-141 side effects — the tolerability record
Nausea is the defining side effect. In the 52-week extension, drug-related nausea was reported by 40.4% of women, flushing by 20.6%, and headache by 12.0% [4]. Nausea is also a notable driver of discontinuation, which is why injection timing and dose strategy have been studied as ways to reduce it [4].
Two further effects belong on the record. The label documents transient increases in blood pressure after dosing, with a corresponding warning [7]. And hyperpigmentation — a darkening of the skin, gums, or breasts — is reported with repeated frequent dosing, attributed to activation of the MC1R receptor in skin [7]. None of these effects is described here with any dose for an individual.
PT-141 reviews — what people report
These are effects described in research-use and patient communities — anecdotal, not clinical evidence, and not verified by controlled trials. They are summarized here for context only, with no doses and no individual recommendations.
People who discuss PT-141 frequently mention a delayed onset, since the compound is taken ahead of anticipated activity rather than on demand. Nausea after dosing is the single most commonly raised complaint in these accounts, echoing the trial data [4]. Some report flushing or a transient headache. Beyond these, online reports vary widely and are not a substitute for the cited trial record above. Where an anecdotal report conflicts with the measured evidence, the measured evidence is what this site treats as established.
PT-141 side effects worth flagging — safety & cautions
The clearest cited caution is cardiovascular. The US prescribing information documents transient blood-pressure increases and contraindicates bremelanotide in people with uncontrolled hypertension or known cardiovascular disease [7]. This is a labeled warning, not a theoretical one.
A second caution is scope. Bremelanotide is approved only for premenopausal women with HSDD; its safety and benefit in men, in postmenopausal women, and for performance are not established by the approval [7][9]. A third is mechanistic and partly theoretical: because MC4R also sits in appetite circuits, high-frequency dosing in early Phase 1 work affected caloric intake and body weight — a pharmacological consideration, not an approved use [2]. Finally, a 2023 Expression of Concern was issued for a 2008 erectile-dysfunction study, so that older finding should be treated as disputed [7]. No second-person dosing appears anywhere on this site.